US2023407341A1PendingUtilityA1
Using Truncated Guide RNAs (tru-gRNAs) to Increase Specificity for RNA-Guided Genome Editing
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
C12N 15/907C12N 9/22C12N 15/63C12Y 301/21004C12N 15/85C07K 14/005C07K 14/195C12N 9/0071C12N 9/1007C12N 9/16C12N 9/96C12N 15/01C12N 15/102C12N 15/1031C12N 15/11C07K 2319/00C07K 2319/01C12N 2710/00033C12N 2770/00033C12Y 114/11C12Y 201/01C12Y 301/00C12N 2800/80C12N 2310/20C07K 2319/80C12N 15/113C12N 9/10
87
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems, using truncated guide RNAs (tru-gRNAs).
Claims
exact text as granted — not AI-modified1 .- 28 . (canceled)
29 . A complex comprising:
a Streptococcus pyogenes Cas9 protein; and a Streptococcus pyogenes gRNA molecule that includes a complementarity region at the 5′ end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif, wherein the gRNA is a single gRNA, and wherein in the presence of an S. pyogenes Cas9 protein, the gRNA complementary region binds and directs the Cas9 protein to the target sequence.
30 . The complex of claim 29 , wherein the Cas9 protein is a catalytically active nuclease.
31 . The complex of claim 29 , wherein the Cas9 protein is a catalytically active nickase.
32 . The complex of claim 29 , wherein the Cas9 protein is a catalytically inactive Cas9 protein.
33 . The complex of claim 29 , wherein the complementarity region of the gRNA consists of 17 nucleotides.
34 . The complex of claim 29 , wherein the complementarity region of the gRNA consists of 18 nucleotides.
35 . A DNA molecule encoding the complex of claim 29 .
36 . A vector comprising the DNA molecule of claim 35 .
37 . A host cell expressing the vector of claim 36 .
38 . A complex comprising:
a Streptococcus pyogenes Cas9 protein; and a Streptococcus pyogenes gRNA molecule that includes a complementarity region at the end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif, wherein the gRNA is a CRISPR RNA (crRNA), and wherein in the presence of an S. pyogenes Cas9 protein, the gRNA complementary region binds and directs the Cas9 protein to the target sequence.
39 . A vector comprising a DNA molecule encoding:
a Streptococcus pyogenes gRNA molecule that includes a complementarity region at the end of the gRNA consisting of 17-18 nucleotides that are complementary to 17-18 consecutive nucleotides of the complementary strand of a target sequence, wherein the target sequence is immediately 5′ of a protospacer adjacent motif,
wherein the gRNA is a single gRNA or a CRISPR RNA (crRNA), and
wherein in the presence of an S. pyogenes Cas9 nuclease, the gRNA complementary region binds and directs the Cas9 nuclease to the target sequence; and
a promoter.
40 . The vector of claim 39 , wherein the promoter is a constitutive promoter.
41 . The vector of claim 39 , wherein the promoter is an inducible promoter.
42 . The vector of claim 39 , wherein the promoter is a weak promoter.
43 . The vector of claim 39 , wherein the expression vector is a bacterial expression vector.
44 . The vector of claim 39 , wherein the expression vector is a eukaryotic expression vector.
45 . The vector of claim 39 , wherein the promoter is an RNA Pol III promoter.
46 . The vector of claim 39 , wherein the promoter is selected from an H1, U6, or 7SK promoter.
47 . The vector of claim 39 , wherein the promoter is a T7 promoter.
48 . A host cell expressing the vector of claim 47 .Join the waitlist — get patent alerts
Track US2023407341A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.